AL-S Pharma Details Planned Phase 3 Trial Design for AP-101 in ALS

03 Nov 2026 0 comments

AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.

Source: NeurologyLive Published 03 Nov 2026 Imported 03 Nov 2026 Relevancy: Not reviewed

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.